Table 5.
Adverse events associated with replacement therapy and logistic regression analysis.
| Treatment Characteristic | Adverse Events (n = 64) | Odds Ratio (95% CI) | p-Value |
|---|---|---|---|
| Type of Replacement Therapy | |||
| - Plasma-derived Factor VIII | 6 (9.4%) | 1.35 (0.76–2.41) | 0.288 |
| - Recombinant Factor VIII | 42 (65.6%) | 0.87 (0.54–1.41) | 0.562 |
| Dosage (IU/kg per week) | |||
| - Median (IQR) | 30 (25–40) IU/kg/week | 1.02 (0.98–1.05) | 0.364 |
| Frequency of Administration | |||
| - Once weekly | 12 (18.8%) | 1.14 (0.98–1.33) | 0.082 |
| - Twice weekly | 18 (28.1%) | ||
| - Three times weekly | 10 (15.6%) | ||
| - Other | 24 (37.5%) | ||
| Duration of Therapy (weeks) | |||
| - Median (IQR) | 28 (24–32) weeks | 0.98 (0.93–1.03) | 0.512 |
| Reason for Therapy Use | |||
| - Bleeding episodes management | 42 (65.6%) | Reference | - |
| - Surgery preparation | 8 (12.5%) | 1.57 (0.84–2.95) | 0.158 |
| - Prophylactic during pregnancy | 14 (21.9%) | 0.92 (0.55–1.55) | 0.762 |
| Switch of Therapy | |||
| - From recombinant to plasma-derived | 1 (1.6%) | 1.23 (0.45–3.38) | 0.678 |
| - From plasma-derived to recombinant | 3 (4.7%) | 0.98 (0.58–1.65) | 0.928 |